Following a multi-year collaboration with Formac Pharmaceuticals , W.R Grace launches SilSolTM 6 as first Excipient GMP Mesoporous silica for Drug delivery in the "Grace Silica based Drug Delivery Platform".

SilSol 6035 is the first result out of more then 6 years of research and development. SilSol6 is developed for optimum pore size and pore size-distribution towards amorphisation, supersaturation and stability improvement for BCS2 compounds.

The launch of this new material will complement  Formac Ordered Mesoporous Materials and offer to pharmaceutical development scientists a panel of options in the field of silica drug delivery.